In a syngeneic lung cancer model, the RBDdopa-BTZ conjugate showed potent antitumor efficacy against ACE2-expressing lung tumors with reduced toxicity in normal ACE2-expressing organs (liver, kidney, and heart). This evidence concerns the gene ACE2 and lung cancer.